Developed through a partnership with Myriad RBM, the Bio-Plex Pro RBM assays enable the detection of multiple biomarkers in a single sample, which may reveal damage within hours of kidney injury. This early detection can improve drug testing in both preclinical and clinical research settings. The toxicity panels contain six of the seven markers approved by the FDA and EMEA for use in preclinical kidney toxicity assessment. Included in these panels are several other markers relevant to kidney toxicity and damage research. The assays are offered as kits that include everything needed to run the assay.